1672 — Ascletis Pharma Balance Sheet
0.000.00%
Last trade - 00:00
- HK$1.30bn
- -HK$1.18bn
- CNY56.60m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2,989 | 2,714 | 2,501 | 2,482 | 2,299 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 106 | 50.4 | 70 | 31.9 | 5.43 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 3,193 | 2,830 | 2,632 | 2,545 | 2,333 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 98.7 | 84.6 | 77.9 | 73 | 68.5 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 3,426 | 3,067 | 2,830 | 2,657 | 2,491 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 87.7 | 73.8 | 91 | 108 | 141 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 102 | 85.4 | 101 | 117 | 149 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 3,324 | 2,982 | 2,729 | 2,540 | 2,342 |
Total Liabilities & Shareholders' Equity | 3,426 | 3,067 | 2,830 | 2,657 | 2,491 |
Total Common Shares Outstanding |